Table: Santen Pharm -Q1 group results (IFRS)
04/08/2022 07:00
Aug 4 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2022 Jun 30, 2021 Mar 31, 2023
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 65.53 64.99 264.00
(+0.8 pct) (+12.9 pct) (-0.8 pct)
Operating 8.33 9.16 34.20
(-9.0 pct) (+14.2 pct) (-4.7 pct)
Pretax 9.07 9.17 32.50
(-1.1 pct) (+9.7 pct) (-8.7 pct)
Net 6.66 7.34
(-9.2 pct) (+18.6 pct)
EPS Basic 16.79 yen 18.36 yen 61.96 yen
EPS Diluted 16.77 yen 18.34 yen
Ann Div 32.00 yen 32.00 yen
-Q2 Div 16.00 yen 16.00 yen
-Q4 Div 16.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T